SPA
IRWD icon

Sherbrooke Park Advisers’s Ironwood Pharmaceuticals IRWD Stock Holding History

Sherbrooke Park Advisers’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,701
Closed -$209K – 964
2024
Q3 		$209K Buy
+50,701
New +$273K 0.05% 738
2024
Q2 		– Sell
-30,074
Closed -$262K – 1055
2024
Q1 		$262K Buy
+30,074
New +$365K 0.05% 622

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Sherbrooke Park Advisers's IRWD Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2024, closing a stake of 50,701 shares — an estimated $209K sold.

Sherbrooke Park Advisers first reported a position in IRWD in Q1 2024 and held it in 2 quarters. The position peaked at $262K in Q1 2024. 223 funds tracked by Wall St. Rank hold IRWD as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Ironwood Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 50,701 Ironwood Pharmaceuticals shares in Q4 2024, an estimated $209K.
  • Sherbrooke Park Advisers first reported a position in Ironwood Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Ironwood Pharmaceuticals position peaked at $262K in Q1 2024.
  • 223 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.